The 7.48x price-to-book ratio is strikingly elevated versus both ADUS (2.06x) and ENSG (4.47x), which partly reflects aggressive buybacks having shrunk equity from $1.2B to $861M over ten quarters rather than pure goodwill repricing. Meanwhile, the 16.96x EV/EBITDA compressing to 12.36x on a forward basis suggests either consensus anticipates an EBITDA inflection or the market is underpricing the reimbursement risk embedded in VITAS's per-diem structure — a tension that warrants careful sum-of-the-parts scrutiny rather than consolidated multiple comparison.

Net margin of 10.4% in Q3 2026 versus 14.1% two years earlier reflects both the operating margin compression (14.0% vs. 17.8%) and the rising interest expense from the debt-funded buyback program. The fact that SG&A as a percentage of revenue has declined from roughly 16.7% to 16.1% over the same window suggests that overhead discipline is partially offsetting the gross margin headwind, but this lever has finite remaining capacity. The true earning power metric here should exclude the volatile stock-based compensation swings — which ranged from -$15.2M to +$23.5M in recent quarters — making adjusted EBITDA a more reliable gauge than GAAP net margin for cross-period comparison.

This divergence between ROE and ROIC is the critical insight: when ROE moves upward while ROIC trends downward, the incremental return is being manufactured by balance sheet engineering rather than core business efficiency. Asset turnover has gradually improved from 0.34 to 0.42 over the period, which provides a modest offset, but the ROIC trajectory of 7.7% to 6.2% over eight quarters suggests the capital base deployed across VITAS and Roto-Rooter is generating progressively less economic profit. For a dual-segment business where Roto-Rooter's franchise model requires limited capital but VITAS's clinical infrastructure is asset-heavy, the blended ROIC obscures which segment is truly compounding versus diluting returns.

Despite this rapid leverage ramp, interest coverage of 47x remains exceptionally comfortable relative to ENSG's 1.86x D/E and even ADUS's 0.19x, suggesting that Chemed could sustain substantially higher debt service without covenant pressure. However, the trajectory — not the absolute level — is the analytical concern: when a historically net-cash company inverts to net-debt in just four quarters, and does so primarily to fund share repurchases rather than accretive acquisitions, the market should scrutinize whether management views the stock as more attractive than organic growth opportunities in a consolidating hospice sector. The D/EBITDA of 3.45x in Q3 2026 (up from 1.09x in Q4 2024) confirms that the leverage increase is real, not merely an equity-decline artifact.